While we have Amazing Search we also deliver a full complement of artifacts from EDGAR to our clients - here is one example
At Sept. 18, 2026, 4:33 p.m., Neuphoria Therapeutics Inc. (CIK: 1191070) reported their Executive Compensation in a recent DEF 14A. Here is the original data:Name and Principal Position |
Fiscal
Year
|
Salary |
Bonus |
Stock
Awards
|
Option
Awards(1)
|
Non-Equity Incentive
Plan Compensation
|
Nonqualified Deferred
Compensation
Earnings
|
All Other
Compensation
|
Total |
||||||||||||||||||
|
Spyros Papapetropoulos, MD.
President and Chief Executive Officer
|
2025 |
$550,000 |
$226,875 |
$— |
$95,850
|
$— |
$— |
$50,808
|
$923,533
|
||||||||||||||||||
|
Spyros Papapetropoulos, MD.(3)
President and Chief Executive Officer
|
2026 |
$284,625 |
$—
|
$— |
$272,325 |
$— |
$— |
$1,117,740 |
$1,674,690 |
||||||||||||||||||
|
Tim Cunningham(2) Chief Financial
Officer
|
2025 |
$—
|
$—
|
$— |
$—
|
$— |
$— |
$254,363
|
$254,363
|
||||||||||||||||||
|
Tim Cunningham Chief Financial
Officer
|
2026 |
$—
|
$—
|
$— |
$—
|
$— |
$— |
$325,894
|
$325,894
|
||||||||||||||||||
| PERSON-NAME | PERSON-TITLE | YEAR | SALARY | BONUS | STOCK | OPTION | NONEQUITY | NQDEFCOMP | OTHER | TOTAL | SEC-NAME | PERSON-CIK | GENDER |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SPYROS PAPAPETROPOULOS MD. | PRESIDENT AND CHIEF EXECUTIVE OFFICER | 2025 | 550000 | 226875 | 95850 | 50808 | 923533 | PAPAPETROPOULOS SPYROS | 1832694 | M | |||
| SPYROS PAPAPETROPOULOS MD. | PRESIDENT AND CHIEF EXECUTIVE OFFICER | 2026 | 284625 | 272325 | 1117740 | 1674690 | PAPAPETROPOULOS SPYROS | 1832694 | M | ||||
| TIM CUNNINGHAM | CHIEF FINANCIAL OFFICER | 2025 | 254363 | 254363 | CUNNINGHAM TIMOTHY M. | 1757426 | M | ||||||
| TIM CUNNINGHAM | CHIEF FINANCIAL OFFICER | 2026 | 325894 | 325894 | CUNNINGHAM TIMOTHY M. | 1757426 | M |